| Secondary |
| Electrolyte Substitution Therapy |
12.3% |
| Stupor |
8.8% |
| Product Used For Unknown Indication |
8.2% |
| Arthritis |
7.6% |
| Hypertension |
7.0% |
| Restlessness |
7.0% |
| Pain |
5.8% |
| Essential Hypertension |
5.3% |
| Cardiac Failure |
4.1% |
| Constipation |
3.5% |
| Depression |
3.5% |
| Hypothyroidism |
3.5% |
| Thrombosis Prophylaxis |
3.5% |
| Blood Pressure |
2.9% |
| Coronary Artery Disease |
2.9% |
| Hyperglycaemia |
2.9% |
| Polyuria |
2.9% |
| Prophylaxis Against Gastrointestinal Ulcer |
2.9% |
| Sepsis |
2.9% |
| Agitation |
2.3% |
|
| Toxic Epidermal Necrolysis |
24.0% |
| Death |
20.0% |
| Oxygen Saturation Decreased |
12.0% |
| Blood Pressure Increased |
4.0% |
| Bradycardia |
4.0% |
| Dementia Alzheimer's Type |
4.0% |
| Drug Interaction |
4.0% |
| Fall |
4.0% |
| Hepatocellular Injury |
4.0% |
| International Normalised Ratio Increased |
4.0% |
| Menstruation Irregular |
4.0% |
| Stevens-johnson Syndrome |
4.0% |
| Torsade De Pointes |
4.0% |
| Toxicity To Various Agents |
4.0% |
|
| Concomitant |
| Product Used For Unknown Indication |
17.3% |
| Drug Use For Unknown Indication |
16.3% |
| Hypertension |
16.0% |
| Psoas Abscess |
6.7% |
| Pain |
6.4% |
| Supplementation Therapy |
6.1% |
| Prophylaxis |
3.7% |
| Atrial Fibrillation |
3.5% |
| Thrombosis Prophylaxis |
2.7% |
| Depression |
2.4% |
| Essential Hypertension |
2.3% |
| Hyperglycaemia |
2.3% |
| Cardiac Disorder |
2.2% |
| Myocardial Ischaemia |
2.0% |
| Restlessness |
1.8% |
| Secretion Discharge |
1.8% |
| Non-small Cell Lung Cancer |
1.7% |
| Renal Impairment |
1.7% |
| Acute Myocardial Infarction |
1.5% |
| Cardiac Failure |
1.5% |
|
| Stevens-johnson Syndrome |
11.9% |
| Death |
7.1% |
| Renal Failure Acute |
7.1% |
| Rhabdomyolysis |
7.1% |
| Dyspnoea |
6.0% |
| Hepatitis Acute |
6.0% |
| General Physical Health Deterioration |
4.8% |
| Haemoptysis |
4.8% |
| Neutropenic Sepsis |
4.8% |
| Toxic Epidermal Necrolysis |
4.8% |
| Tremor |
4.8% |
| Vomiting |
4.8% |
| Coronary Artery Disease |
3.6% |
| Coronary Artery Restenosis |
3.6% |
| Drug Exposure During Pregnancy |
3.6% |
| Respiratory Failure |
3.6% |
| Tooth Disorder |
3.6% |
| Weight Decreased |
3.6% |
| Abortion Induced |
2.4% |
| Blood Potassium Increased |
2.4% |
|
| Interacting |
| Atrial Fibrillation |
28.6% |
| Glaucoma |
28.6% |
| Arrhythmia |
14.3% |
| Atrial Flutter |
14.3% |
| Hyperthyroidism |
14.3% |
|
| Cardiogenic Shock |
33.3% |
| Drug Interaction |
33.3% |
| White Blood Cell Count Increased |
33.3% |
|
